View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Progr...

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that its Board of Directors has authorized a new share repurchase program to repurchase up to $200 million of shares of Catalyst's outstanding common stock between October 1, 2025, and December 31, 202...

PBF Energy Inc: 2 directors

Two Directors at PBF Energy Inc sold after exercising options/sold 110,000 shares at between 34.000USD and 34.134USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the...

 PRESS RELEASE

Lesaka’s Final FY2025 Results: Delivers on FY2025 Profitability Guidan...

Lesaka’s Final FY2025 Results: Delivers on FY2025 Profitability Guidance, Reaffirms FY2026 Profitability & Net Revenue Outlook, and Sets FY2026 Profitability per Share Guidance, reflecting more than 100% Year-on-Year Growth JOHANNESBURG, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the fourth quarter (“Q4 2025”) and full year of fiscal 2025 (“FY2025”). FY2025 performance:All growth rates are year-on-year between FY2025 and FY2024. Revenue of $659.7 million (ZAR 12.0 billion) up 14% in ZAR.Net...

 PRESS RELEASE

Steelcase Reports Second Quarter Fiscal 2026 Results

Steelcase Reports Second Quarter Fiscal 2026 Results Revenue grew 5% compared to prior year, led by strong growth from large corporate customers in the Americas and from the India market in InternationalGross margin of 34.4% was approximately flat compared to prior year despite higher tariff and restructuring costsOrders grew 6% compared to prior year, led by continued growth from large corporate customers in the Americas GRAND RAPIDS, Mich., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Steelcase Inc. (NYSE: SCS) today reported second quarter revenue of $897.1 million, net income of $35.0 million,...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Steelcase to Webcast Second Quarter Fiscal 2026 Conference Call

Steelcase to Webcast Second Quarter Fiscal 2026 Conference Call GRAND RAPIDS, Mich., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Steelcase Inc. (NYSE: SCS) will webcast a discussion of its second quarter fiscal year 2026 financial results on Thursday, September 25, 2025 at 8:30 a.m. ET. A link to the webcast will be available at and a replay of the webcast will be available shortly after the call concludes. The news release detailing the financial results will be issued the previous day, September 24, 2025, after the market closes.  About Steelcase Inc.  Steelcase (NYSE: SCS) is a global design...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 10, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Lesaka Announces Preliminary FY2025 Results, Delivers on FY2025 Profit...

Lesaka Announces Preliminary FY2025 Results, Delivers on FY2025 Profitability Guidance, Reaffirms FY2026 Profitability Outlook, and Sets FY2026 Profitability per Share Guidance, reflecting more than 100% Year-on-Year Growth JOHANNESBURG, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released preliminary unaudited results for the fourth quarter (“Q4 2025”) and full year of fiscal 2025 (“FY2025”). FY2025 performance:All growth rates are year-on-year between FY2025 and FY2024. Net Revenue (a non-GAAP measure) of $328.7 million (ZAR 5.3 billion)...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

nsiderInsights Weekly Report: August 30, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferenc...

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below. 2025 Wells Fargo H...

 PRESS RELEASE

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (a...

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licenso...

 PRESS RELEASE

Lesaka to Host Webcast and Conference Call to Review Fourth Quarter an...

Lesaka to Host Webcast and Conference Call to Review Fourth Quarter and Year-End 2025 Results on September 11, 2025 JOHANNESBURG, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ:, JSE: LSK) ("Lesaka") now intends to release fourth quarter and year-end 2025 results after the U.S. market close on September 10, 2025. Lesaka management will host a presentation webcast and conference call on September 11, 2025, at 8:00am EDT (2:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: ...

 PRESS RELEASE

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifamprid...

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A....

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half ...

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year 2025 Total Revenue Guidance of $545 Million to $565 Million, Reflecting Broad-Based Growth and Sustained Demand FIRDAPSE® Q2 2025 Net Product Revenue of $84.8 Million, Up 9.7% YoY; First Half 2025 Net ...

 PRESS RELEASE

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatmen...

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC) VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a supportive care treatmentGuideline inclusion may raise clinical awareness of cancer-associated LEMS to support broader VGCC diagnostic testing and treatment adoption CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-st...

 PRESS RELEASE

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of D...

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Ch...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch